• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Set to Join S&P MidCap 400

    5/29/24 5:48:00 PM ET
    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $JNJ alert in real time by email

    NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    June 3, 2024

    S&P MidCap 400

    Addition

    Sarepta Therapeutics

    SRPT

    Health Care

    June 3, 2024

    S&P MidCap 400

    Deletion

    Shockwave Medical

    SWAV

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html

    SOURCE S&P Dow Jones Indices

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $JNJ
    $SPGI
    $SRPT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/18/2025Buy → Hold
    Needham
    Sarepta Therapeutics Inc.
    $SRPT
    6/20/2025Outperform → Mkt Perform
    William Blair
    Sarepta Therapeutics Inc.
    $SRPT
    6/18/2025$24.00Buy → Hold
    TD Cowen
    Sarepta Therapeutics Inc.
    $SRPT
    6/17/2025Peer Perform
    Wolfe Research
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025Overweight → Equal-Weight
    Morgan Stanley
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025Overweight → Neutral
    Cantor Fitzgerald
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025Buy → Neutral
    BofA Securities
    Sarepta Therapeutics Inc.
    $SRPT
    6/16/2025$70.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Innovative Medicine, R&D Reed John C sold $3,129,830 worth of shares (19,137 units at $163.55), decreasing direct ownership by 64% to 10,658 units (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      7/18/25 4:12:41 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Pinto Daniel E claimed no ownership of stock in the company (SEC Form 3)

      3 - JOHNSON & JOHNSON (0000200406) (Issuer)

      7/8/25 5:31:26 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hewson Marillyn A

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      6/12/25 4:32:25 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    SEC Filings

    See more
    • Sarepta Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Leadership Update, Financial Statements and Exhibits

      8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

      7/16/25 4:11:10 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - JOHNSON & JOHNSON (0000200406) (Filer)

      7/16/25 8:06:45 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 11-K filed by S&P Global Inc.

      11-K - S&P Global Inc. (0000064040) (Filer)

      6/25/25 6:16:08 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sarepta Therapeutics downgraded by Needham

      Needham downgraded Sarepta Therapeutics from Buy to Hold

      7/18/25 11:47:07 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics downgraded by William Blair

      William Blair downgraded Sarepta Therapeutics from Outperform to Mkt Perform

      6/20/25 7:52:50 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sarepta Therapeutics downgraded by TD Cowen with a new price target

      TD Cowen downgraded Sarepta Therapeutics from Buy to Hold and set a new price target of $24.00

      6/18/25 7:45:18 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

      7/12/24 4:40:36 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

      For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

      6/20/24 5:24:42 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

      Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

      6/5/24 4:41:31 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

      4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

      8/20/24 8:00:04 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

      4 - S&P Global Inc. (0000064040) (Issuer)

      6/17/24 4:04:40 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sarepta Therapeutics Provides Statement on ELEVIDYS

      Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Shortly after 2:30 p.m. ET today, Sarepta received an informal request from the U.S. Food and Drug Administration (FDA) to voluntarily halt shipment of ELEVIDYS (delandistrogene moxeparvovec), our gene therapy for Duchenne muscular dystrophy (Duchenne), in the U.S. We first heard of this potential request earlier in the day at the same time the public and our patient communities did, through media reports. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our

      7/18/25 7:39:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Block Set to Join S&P 500

      NEW YORK, July 18, 2025 /PRNewswire/ -- Block Inc. (NYSE:XYZ) will replace Hess Corp. (NYSE:HES) in the S&P 500 effective prior to the opening of trading on Wednesday, July 23. S&P 500 and S&P 100 constituent Chevron Corp. (NYSE: CVX) has acquired Hess Corp in a deal that closed today, July 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector July 23, 2025 S&P 500 Addition Block XYZ Financials July 23, 2025 S&P 500 Deletion Hess HES Energy For more information about S&P Dow Jones Indices, please visit www.spdji.com.  ABOUT S&P DOW JONES INDICES S&P Dow Jones Indi

      7/18/25 6:02:00 PM ET
      $CVX
      $HES
      $SPGI
      $XYZ
      Integrated oil Companies
      Energy
      Finance: Consumer Services
      Finance
    • S&P Dow Jones Indices Announces Changes to the S&P/TSX Composite Index

      TORONTO, July 18, 2025 /CNW/ - The shareholders of Innergex Renewable Energy Inc. (TSX:INE) have agreed to the terms of a Plan of Arrangement resulting in the acquisition by La Caisse. Each share of Innergex Renewable Energy will receive $13.75 cash consideration. Innergex Renewable Energy shares will be removed from the S&P/TSX Composite Index prior to the open of trading on Wednesday, July 23, 2025. For more information about S&P Dow Jones Indices, please visit www.spdji.com. ABOUT S&P DOW JONES INDICES S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow

      7/18/25 5:15:00 PM ET
      $SPGI
      Finance: Consumer Services
      Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Financials

    Live finance-specific insights

    See more
    • Sarepta Therapeutics Announces Strategic Restructuring and Pipeline Prioritization Plan to Maintain Long-term, Sustainable Growth and Provides Update on ELEVIDYS Label

      – After strategic review, Sarepta focuses pipeline on high-impact programs, prioritizing potentially best-in-class siRNA platform assets – Strategic restructuring includes reduced operating expenses, delivering approximately $400 million in anticipated annual cost savings, and implementing a 36% workforce reduction of approximately 500 employees – Duchenne portfolio continues to deliver stable and robust revenues, with preliminary quarterly results showing total net product revenue of $513 million for the second quarter 2025 – U.S. FDA has requested and Sarepta has agreed to include a black box warning in the ELEVIDYS label, resolving any material issues with the ambulant population i

      7/16/25 4:01:00 PM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025

      Johnson & Johnson (NYSE:JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2025 of $1.30 per share on the company's common stock. The dividend is payable on September 9, 2025 to shareholders of record at the close of business on August 26, 2025. The ex-dividend date is August 26, 2025. About Johnson & Johnson At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely po

      7/16/25 6:25:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Johnson & Johnson Reports Q2 2025 Results; Raises 2025 Outlook

      2025 Second-Quarter reported sales growth of 5.8% to $23.7 Billion with operational growth of 4.6%* and adjusted operational growth of 3.0%* 2025 Second-Quarter reflects earnings per share (EPS) of $2.29 and adjusted EPS of $2.77 Significant new product pipeline progress including approval of IMAAVY for generalized myasthenia gravis, priority review for TAR-200, data for CARVYKTI overall survival and progression-free benefits in multiple myeloma, and continuation of the clinical trial for a general surgery robotic system, OTTAVA Strong operational performance and favorable foreign exchange results in Company increasing full year estimated reported sales5 guidance at the midpoint b

      7/16/25 6:20:00 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    See more
    • Block Set to Join S&P 500

      NEW YORK, July 18, 2025 /PRNewswire/ -- Block Inc. (NYSE:XYZ) will replace Hess Corp. (NYSE:HES) in the S&P 500 effective prior to the opening of trading on Wednesday, July 23. S&P 500 and S&P 100 constituent Chevron Corp. (NYSE: CVX) has acquired Hess Corp in a deal that closed today, July 18. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector July 23, 2025 S&P 500 Addition Block XYZ Financials July 23, 2025 S&P 500 Deletion Hess HES Energy For more information about S&P Dow Jones Indices, please visit www.spdji.com.  ABOUT S&P DOW JONES INDICES S&P Dow Jones Indi

      7/18/25 6:02:00 PM ET
      $CVX
      $HES
      $SPGI
      $XYZ
      Integrated oil Companies
      Energy
      Finance: Consumer Services
      Finance
    • AeroVironment Set to Join S&P MidCap 400; Victory Capital Holdings to Join S&P SmallCap 600

      NEW YORK, July 15, 2025 /PRNewswire/ -- AeroVironment Inc. (NASD: AVAV) will replace ChampionX Corp. (NASD: CHX) in the S&P MidCap 400, and Victory Capital Holdings Inc. (NASD: VCTR) will replace AeroVironment in the S&P SmallCap 600 effective prior to the opening of trading on Friday, July 18. S&P 500 constituent Schlumberger Ltd. (NYSE:SLB) is acquiring ChampionX in a deal expected to be completed July 16, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 18, 2025 S&P MidCap 400 Addition AeroVironment AVAV Industrials J

      7/15/25 5:44:00 PM ET
      $AVAV
      $CHX
      $SLB
      $SPGI
      Aerospace
      Industrials
      Industrial Machinery/Components
      Oilfield Services/Equipment
    • The Trade Desk Set to Join S&P 500

      NEW YORK, July 14, 2025 /PRNewswire/ -- The Trade Desk Inc. (NASD: TTD) will replace ANSYS Inc. (NASD: ANSS) in the S&P 500 effective prior to the opening of trading on Friday, July 18. S&P 500 constituent Synopsys Inc. (NASD: SNPS) will acquire ANSYS in a deal expected to be completed on July 17. Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name  Action Company Name Ticker GICS Sector July 18, 2025 S&P 500 Addition The Trade Desk TTD Communication Services July 18, 2025 S&P 500 Deletion ANSYS ANSS Information Technology For more information about S&P Dow Jones Indices, please visit www.spdji.com  ABOUT S&

      7/14/25 5:39:00 PM ET
      $ANSS
      $SNPS
      $SPGI
      $TTD
      Computer Software: Prepackaged Software
      Technology
      Finance: Consumer Services
      Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

      SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

      11/13/24 10:27:59 AM ET
      $SRPT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Johnson & Johnson

      SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

      4/10/24 5:12:55 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

      SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

      2/13/24 5:13:59 PM ET
      $SWAV
      Medical/Dental Instruments
      Health Care